SCYNEXIS/$SCYX
1D1W1MYTD1Y5YMAX
Capital at risk
About SCYNEXIS
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
- Ticker
- $SCYX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 18
- Headquarters
- Jersey City, United States
- Website
- www.scynexis.com
SCYNEXIS Metrics
BasicAdvanced
$49M
-
-$1.33
1.10
-
Price and volume
Market cap
$49M
Beta
1.1
52-week high
$9.12
52-week low
$3.53
Average daily volume
349K
Financial strength
Current ratio
9.654
Quick ratio
9.285
Long term debt to equity
0.021
Total debt to equity
0.029
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-53.26%
Operating margin (TTM)
-117.61%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
-20.82%
Return on equity (TTM)
-18.38%
Valuation
Price to revenue (TTM)
1.979
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-2.858
Free cash flow yield (TTM)
-34.99%
Free cash flow per share (TTM)
-1.729
Growth
Revenue change (TTM)
489.99%
Earnings per share change (TTM)
-58.18%
3-year revenue growth (CAGR)
-47.87%
10-year revenue growth (CAGR)
53.95%
3-year earnings per share growth (CAGR)
-43.69%
10-year earnings per share growth (CAGR)
-38.86%
SCYNEXIS Financial Performance
Revenues and expenses
SCYNEXIS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.